Emerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment
Available resources of the Center include human pathology specimens and database info on living consented patients. Techniques such as tissue imaging, gene expression analysis, T-cell receptor, sequencing studies, and CyTOF analyses are available. Visiting Scholar grants funds allow researchers to learn how to work with human tissue and how to use new techniques.
It is not uncommon to hear people talk about the health of their practices by confidently stating how far they are “booked out.” How long it takes for a patient to get an appointment is often a statement of practice wellness.
With much of the digital revolution occurring after 2008 and most contact lens technology developing well before it, there is an inherent design feature mismatch. The majority of the available contact lenses are not designed for how patients are using their eyes.
Chronic dry eye disease (DED) affects more than 25 million people and to date the only pharmacologic therapies are topical or involve punctal plugs. Results from two studies wth a neurostimulator indicate there may be a new pathway to upregulate the body’s tear system.
A 19-month, open-label study of a novel bimatoprost, sustained-release ocular insert shows good safety and efficacy. The insert is polymer ring that sits atop the eye in the conjunctival fornix. Phase III trials are expected to begin in 2017.